RxDoctor Payments Data

Mazin Yonan, MD

Internal Medicine · Troy, MINPI 1801888904

Payments from drug & device makers

$9,405in general payments, 2019–2025

Across 462 payments — averaging $20.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • Lilly USA, LLC$1K
  • Amgen$1K
  • AstraZeneca$786
  • AbbVie$758
  • Pfizer$576
  • plus $3K from 37 others

What the payments were for

  • Speaking & faculty fees$1111%
  • Food & beverage$9,29399%
  • Education$10%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,405 in reported general payments places this provider in the 95th percentile of 4,567 internal medicine providers in Michigan.

See all internal medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$202,889
Medicare patients
175
Services billed
2,613

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban215$205,211
JardianceEmpagliflozin206$188,304
TrulicityDulaglutide105$113,938
MounjaroTirzepatide56$72,752
Trelegy ElliptaFluticasone/Umeclidin/Vilanter93$69,494
OzempicSemaglutide58$58,895
LinzessLinaclotide73$55,737
RybelsusSemaglutide29$43,135
GemtesaVibegron62$40,513
ProliaDenosumab24$40,417
JanuviaSitagliptin Phosphate56$40,033
XareltoRivaroxaban32$27,826
VascepaIcosapent Ethyl68$23,693
FarxigaDapagliflozin Propanediol19$19,099
Novolog FlexpenInsulin Aspart84$18,077

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$576$205,211215 claims
Boehringer IngelheimJardiance$325$188,304206 claims
Lilly USA, LLCTrulicity, Mounjaro$1,252$186,689161 claims
Novo NordiskOzempic, Rybelsus$1,497$102,03087 claims
GSKTrelegy Ellipta, Breo Ellipta$231$86,271131 claims
AbbVieLinzess, Restasis$758$64,32185 claims
Sumitomo Pharma America, Inc.Gemtesa$215$40,51362 claims
AmgenProlia$1,216$40,41724 claims
MerckJanuvia$23$40,03356 claims
Johnson & JohnsonXarelto$66$27,82632 claims
AstraZenecaFarxiga$786$19,09919 claims
Astellas Pharma US IncMyrbetriq$41$13,72215 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,567 internal medicine providers in Michigan.

Other internal medicine in Troy

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →